Compare UNCY & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UNCY | ANIK |
|---|---|---|
| Founded | 2016 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.9M | 142.5M |
| IPO Year | 2021 | 1993 |
| Metric | UNCY | ANIK |
|---|---|---|
| Price | $6.06 | $9.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $44.50 | $16.00 |
| AVG Volume (30 Days) | ★ 451.4K | 165.4K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $112,806,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19,392.60 | $4.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 30.55 |
| 52 Week Low | $3.71 | $7.87 |
| 52 Week High | $11.00 | $18.37 |
| Indicator | UNCY | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 61.73 | 44.10 |
| Support Level | $5.96 | $9.76 |
| Resistance Level | $6.70 | $10.17 |
| Average True Range (ATR) | 0.46 | 0.36 |
| MACD | 0.06 | -0.04 |
| Stochastic Oscillator | 63.68 | 22.33 |
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.